Orchid BioSciences grants license to Quest Diagnostics

17-Dec-2001
Orchid BioSciences, Inc. has granted a non- exclusive license to Quest diagnostics Incorporated covering the commercial use of Orchid's proprietary SNP-IT technology for gene-based diagnostic testing services using SNAPshot reagent kits marketed by Applied Biosystems Group. Orchid received an upfront payment and will earn royalties on all diagnostic services performed by Quest Diagnostics using Orchid technology under this agreement. Further details were not disclosed. "This agreement with Quest Diagnostics is highly significant for Orchid on several fronts," said Donald R. Marvin, chief operating officer of Orchid and acting general manager of Orchid Diagnostics, a newly formed strategic business unit at the company. "It is the first license of our market leading SNP scoring technology to the diagnostics field, and we are especially pleased that our collaborator is Quest Diagnostics, the leading provider of diagnostic services in the U.S. and an acknowledged diagnostics innovator." Quest Diagnostics is the first laboratory to obtain a license to offer commercial genotyping services using Orchid's SNP-IT technology. SNAPshot assays based on the Orchid technology are particularly suitable for high-volume tests involving three to five SNP markers. Quest Diagnostics will develop new diagnostic tests using Orchid's SNP-IT technology embedded in SNAPshot reagent kits marketed by Applied Biosystems Group.

Other news from the department research and development

Most read news

More news from our other portals

Discover the latest developments in battery technology!